Literature DB >> 1531876

The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.

J A DeCaprio1, Y Furukawa, F Ajchenbaum, J D Griffin, D M Livingston.   

Abstract

The retinoblastoma-susceptibility gene product (RB) undergoes cell cycle-dependent phosphorylation and dephosphorylation. We characterized RB phosphorylation after mitogenic stimulation of primary human T lymphocytes, initially arrested in the G0 state. RB is phosphorylated in at least three steps when T cells are driven into the cell cycle. The first event occurs during mid G1 phase, the second during S phase, and the third in G2/M. Tryptic phosphopeptide mapping indicates that the different phosphorylation events occur, at least in part, on different residues in RB. Given the known relationship of the RB phosphorylation state to function, it is possible that RB regulates growth at multiple points in the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531876      PMCID: PMC48539          DOI: 10.1073/pnas.89.5.1795

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor.

Authors:  L R Bandara; N B La Thangue
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

2.  The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein.

Authors:  T Chittenden; D M Livingston; W G Kaelin
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

3.  In vitro phosphorylation of the tumor suppressor gene RB protein by mitosis-specific histone H1 kinase.

Authors:  Y Taya; H Yasuda; M Kamijo; K Nakaya; Y Nakamura; Y Ohba; S Nishimura
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

4.  Contingent genetic regulatory events in T lymphocyte activation.

Authors:  G R Crabtree
Journal:  Science       Date:  1989-01-20       Impact factor: 47.728

5.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element.

Authors:  J A DeCaprio; J W Ludlow; D Lynch; Y Furukawa; J Griffin; H Piwnica-Worms; C M Huang; D M Livingston
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

6.  Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line.

Authors:  A Weiss; J D Stobo
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

7.  A monoclonal antibody blocking human T cell function.

Authors:  E L Reinherz; R E Hussey; S F Schlossman
Journal:  Eur J Immunol       Date:  1980-10       Impact factor: 5.532

8.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.

Authors:  P L Chen; P Scully; J Y Shew; J Y Wang; W H Lee
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

9.  The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells.

Authors:  H J Xu; S X Hu; T Hashimoto; R Takahashi; W F Benedict
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

10.  A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway.

Authors:  M Mudryj; S W Hiebert; J R Nevins
Journal:  EMBO J       Date:  1990-07       Impact factor: 11.598

View more
  60 in total

1.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  MDM2/p53 protein expression in the development of colorectal adenocarcinoma.

Authors:  G Abdel-Fattah; B Yoffe; B Krishnan; V Khaoustov; K Itani
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

3.  Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes.

Authors:  P D Adams; X Li; W R Sellers; K B Baker; X Leng; J W Harper; Y Taya; W G Kaelin
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Low- and high-risk human papillomavirus E7 proteins regulate p130 differently.

Authors:  Lisa Barrow-Laing; Wei Chen; Ann Roman
Journal:  Virology       Date:  2010-02-26       Impact factor: 3.616

5.  Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest.

Authors:  G S Dbaibo; M Y Pushkareva; S Jayadev; J K Schwarz; J M Horowitz; L M Obeid; Y A Hannun
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

8.  Genomic structure of the human retinoblastoma-related Rb2/p130 gene.

Authors:  A Baldi; V Boccia; P P Claudio; A De Luca; A Giordano
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control.

Authors:  K F Harris; J B Christensen; M J Imperiale
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein.

Authors:  G P Dimri; M Nakanishi; P Y Desprez; J R Smith; J Campisi
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.